Prevalence of Dermatitis Herpetiformis in iCureCeliac Patient Registry
The following study, which examines the prevalence of dermatitis herpetiformis (DH), was made possible by the Foundation’s iCureCeliac® patient registry.
Continue ReadingThe following study, which examines the prevalence of dermatitis herpetiformis (DH), was made possible by the Foundation’s iCureCeliac® patient registry.
Continue ReadingThe Celiac Disease Foundation is pleased to have partnered with the Columbia University Celiac Disease Center and Farncombe Family Digestive Health Research Institute at McMaster University Medical Center to recruit patients for an international study that found those with celiac disease are not at an increased risk of contracting COVID-19.
Continue ReadingThe Foundation is pleased to announce its partnership with Provention Bio to provide clinical trial recruitment for its Phase 2b PROACTIVE Celiac Study for PRV-015 (an anti-interleukin-15 monoclonal antibody).
Continue ReadingPROACTIVE Celiac Study is a phase 2 clinical trial testing the investigational medication PRV-015. In combination with a gluten-free diet, PRV-015 aims to reduce symptoms and intestinal inflammation caused by accidental gluten exposure.
Continue ReadingThe ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.
Continue ReadingCDF has been approved for a $100,000 funding award through the Eugene Washington PCORI Engagement Awards program. The funds will support the community convening of patient advocates, researchers, and other key stakeholders to create a roadmap for patient advocate engagement in research.
Continue ReadingPeople with celiac disease have a 10-fold greater risk for inflammatory bowel disease (IBD). Those with IBD have a 4-fold greater risk for celiac disease. A new study reviews the link between these two autoimmune disorders.
Continue ReadingTAK-062, an orally administered synthetic enzyme that survives the acidity of the stomach and digests gluten effectively, has passed its phase 1 clinical drug trial, indicating it is safe to use in celiac patients.
Continue ReadingShowcasing the “brightest ideas and breakthroughs in digestive disease,” DDW 2020 includes recent studies and innovations in celiac disease and gluten-related disorders, some of which we have curated and summarized for you.
Continue ReadingA small pilot study suggests chemical pollutants might be an environmental factor associated with celiac disease in children. This is the first research to link the autoimmune disorder with persistent organic pollutants (POPs) detected in blood samples from celiac patients.
Continue Reading